Morphinan derivatives for the treatment of neuropathic pain
AssigneeNektar Therapeutics
InventorsNeel K. Anand, Natalia Aurrecoechea, Lin Cheng, Bo-Liang Deng, Donogh John Roger O'Mahony, YongQi Mu, Erik Krogh-Jespersen
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.
Claims8
A compound of Formula I:
- wherein:
- R1 is —N(R17)(R18);
- R2, R3, R4, R5, R6, R7 R9, R19, and R11 are hydrogen;
- R8 is —CH3;
- R17 is a heteroaryl substituted with —X-POLY;
- R18 is hydrogen;
- X is a linker;
- POLY is a poly(alkylene oxide);
- and
- pharmaceutically acceptable salts thereof.
A method for treating an individual in need of treatment for neuropathic pain, the method comprising the step of administering to the individual a compound having the following formula:
- wherein:
- R1 is —N(R17)(R18);
- R2, R3, R4, R5, R6, R7, R9, R10, and R11 are hydrogen
- R8 is —CH3;
- R17 is a heteroaryl substituted with X-POLY;
- R18 is hydrogen;
- X is a linker;
- POLY is a poly(alkylene oxide);
- and
- pharmaceutically acceptable salts thereof.
A composition of matter comprising a compound of 1, wherein the compound is present in a dosage form.
Dependencies are inferred from the claim text.